Because LCMV can induce robust long-term CD8+ cytotoxic T lymphocyte responses against virus antigens, attenuated recombinant LCMV has been proposed as a tumor immunotherapy platform to deliver tumor-associated antigens (37). Here, CD8A is linked to neoplasm.